Zevra Therapeutics Inc (ZVRA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Zevra Therapeutics Inc   (NASDAQ: ZVRA)


Zevra Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Zevra Therapeutics Inc's ROI in the second quarter of 2026?
Zevra Therapeutics Inc achieved a return on average invested assets (ROI) of 23.75 % in its second quarter of 2026, this is above ZVRA's average return on investment of -124.28%.
Zevra Therapeutics Inc invested over the 12 months ending in its second quarter of 2026 $244 million

ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.

Within the Healthcare sector 43 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 90 to 92.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 44.61 % 69.12 % 60.8 % 55.04 % 51.44 %
Y / Y Net Income Change TTM 2090.02 % - - - -
Investment (TTM) in Millions 254 232 245 244 227
Return On Investment (TTM) 23.75 % 52.39 % 38.59 % 18.56 % 1.57 %
ZVRA's Overall Ranking # 92 # 90 # 75 # 273 # 1724
Seq. Investment Change TTM 2.81 % 9.95 % 13.32 % 12.89 % 20.24 %
Seq. Net Income Change TTM -53.39 % 49.25 % 135.61 % 1236.04 % -
Net Income (TTM) in Millions 58 124 83 35 3

ZVRA Company Profile >> Back to ZVRA Roi Comparisons >> See Annual ZVRA Return On Investment



Return On Investment ZVRA's Ranking
Within: No.
Industry # 22
Sector # 44
Overall # 92

Return On Investment Statistics
High Average Low
50.45 %
-124.28 %
-942.61 %
(Mar 31 2026)   (Dec 31 2019)



  News about Zevra Therapeutics Inc Return on Investment ROI

Zevra Therapeutics Announces Organizational Changes

December 6, 2024

Article for the CSI MarketZevra Therapeutics: Transformational Challenges Amidst Financial Strain in Rare Disease TherapeuticsCELEBRATION, Fla. — In a striving industry defined by rapid innovation and harsh competition, Zevra Therapeutics, Inc. (NASDAQ: ZVRA) finds itself at a critical juncture. The company, dedicated to addressing the unmet therapeutic needs of patients afflicted by rare diseases, recently implemented significant organizational changes aimed at redefining its future trajectory. Yet, behind this ambitious transformation lurks a troubling financial backdrop that raises questions about its sustainability.As of the third quarter of 2024, Zevra recorded a staggering cumulative net loss of $85 million, translating to a disconcerting return on investment (ROI) of -69.18%. With these figures, it becomes apparent why the company is shifting gears; it currently ranks below 3,200 other companies within the healthcare sector in terms of ROI, a clear signal of financial instability. This downward trend forced Zevra into a performance re-evaluation, prompting its latest strategic overhaul.





Financial Statements
Zevra Therapeutics Inc's II. Quarter Investments $ 254 Millions ZVRA's Balance sheet
Zevra Therapeutics Inc's II. Quarter Income $ 8 Millions Quarterly ZVRA's Income Statement
ZVRA's Income by Division See ZVRA's Income by Division


ZVRA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 245 144 99 104 129
Y / Y Investment Growth 70.38 % 46.1 % -5.01 % -19.35 % 3404.25 %
Net Income in Millions 83 -106 -46 -42 -9
Y / Y Net Income Growth - - - - -
Annual Return On Investment 33.91 % -73.24 % -46.7 % -40.02 % -6.65 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 33.91 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ZVRA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ZVRA's Competitors
Subscribers only: Roi for Zevra Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for ZVRA's Customers

Other Ratios
ZVRA's Roa ZVRA's Inventory Turnover Ratio ZVRA's Growth Rates ZVRA's Dividend Statistics
ZVRA's Profitability Ratios ZVRA's Asset Turnover Ratio ZVRA's Dividend Growth
ZVRA's Roe ZVRA's Valuation Ratios ZVRA's Financial Strength Ratios ZVRA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %

Date modified: 2026-09-09T22:33:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.